you are here: HomeNewsBusiness
Last Updated : Mar 27, 2020 04:24 PM IST | Source: PTI

Biocon, Biocon Biologics activate business continuity plans across functions in wake of COVID-19

Biocon will continue to operate essential pharmaceutical manufacturing in full compliance with government requirements, it added.

PTI
Biocon
Biocon
 
 
live
  • bselive
  • nselive
Volume
Todays L/H
More

Biotechnology major Biocon and its arm Biocon Biologics have activated business continuity plans across their functions to prepare for unforeseen events in light of the evolving COVID-19 situation. The plans have been activated also to meet the needs of patients, partners, customers and other stakeholders, Biocon said in a filing to the BSE.

Biocon will continue to operate essential pharmaceutical manufacturing in full compliance with government requirements, it added.

"Since we are involved in manufacturing of essential drugs, we are assessing the impact of the lockdown on our ability to continue with manufacturing operations of essential pharmaceuticals, biopharmaceuticals and APIs in order to meet our commitments to patients, customers and partners," it added.

Close

While supply chain disruptions and impaired mobility due to lockdowns have a direct bearing on the operations, "we are working to minimise disruption to production schedules and supply of drugs...," Biocon said.

COVID-19 Vaccine

Frequently Asked Questions

View more
How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

View more
Show
The current inventory of most of "our raw materials for the company is estimated to last for the next few months," it added. Shares of Biocon were trading at Rs 276.35 per scrip, down 2.33 percent, on the BSE.
First Published on Mar 27, 2020 04:23 pm
Sections